Valuation: Orthocell Limited

Market Cap 208M 144M 128M 120M 109M 206M 13.89B 1.45B 561M 7.07B 541M 530M 22.71B P/E 2027 *
-15.3x
P/E 2028 * -38.3x
Enterprise Value 180M 125M 111M 104M 94.49M 178M 12.02B 1.25B 486M 6.12B 469M 459M 19.66B EV / Sales 2027 *
9.49x
EV / Sales 2028 * 4.83x
Free-Float
83.41%
Yield 2027 *
-
Yield 2028 * -
1 day-0.65%
1 week+2.70%
Current month-0.65%
1 month+5.56%
3 months+5.56%
6 months-5.59%
Current year-29.95%
1 week 0.74
Extreme 0.735
0.79
1 month 0.67
Extreme 0.67
0.8
Current year 0.67
Extreme 0.67
1.16
1 year 0.67
Extreme 0.67
1.58
3 years 0.32
Extreme 0.322
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member 60 21/03/2006
Director/Board Member 60 08/03/2023
Chairman - 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
20/7/26 Buy

Chairman

15,430 0.0057%
17/7/26 Buy 11,573 0.0043%
17/7/26 Buy

Director

16,603 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-0.65%+2.70%-50.33%+100.00% 144M
-3.34%-3.81%+22.95%+28.91% 241B
-4.42%-5.37%-0.53%-14.65% 149B
-1.33%+0.43%-8.40%+37.27% 142B
-0.96%-3.25%-54.90%-18.12% 62.65B
-1.31%-0.63%+11.64%+22.96% 49.1B
-3.27%-3.56%+20.28%+49.06% 46.99B
+0.76%-0.08%-19.51%-21.45% 47.13B
-1.23%+2.58%-3.86%+38.57% 45.65B
-3.15%-1.11%+33.06%+55.18% 41.81B
Average -1.89%+0.07%-4.96%+27.77% 82.54B
Weighted average by Cap. -2.52%+0.45%+3.19%+18.72%

Financials

2027 *2028 *
Net sales 19M 13.15M 11.68M 10.92M 9.96M 18.74M 1.27B 132M 51.16M 645M 49.38M 48.31M 2.07B 38M 26.3M 23.36M 21.85M 19.91M 37.48M 2.53B 264M 102M 1.29B 98.76M 96.62M 4.14B
Net income -13M -9M -7.99M -7.47M -6.81M -12.82M -866M -90.43M -35.01M -441M -33.79M -33.05M -1.42B -5.25M -3.63M -3.23M -3.02M -2.75M -5.18M -350M -36.52M -14.14M -178M -13.64M -13.35M -572M
Net Debt -28M -19.38M -17.22M -16.1M -14.67M -27.62M -1.87B -195M -75.4M -950M -72.77M -71.19M -3.05B -24.65M -17.06M -15.16M -14.17M -12.92M -24.32M -1.64B -171M -66.38M -837M -64.07M -62.68M -2.69B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
02/10/26 $0.7600 -0.65% 313,401
01/10/26 $0.7650 0.00% 308,384
30/09/26 $0.7650 +2.68% 309,226
29/09/26 $0.7450 0.00% 31,816
28/09/26 $0.7450 +0.68% 387,715
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7650AUD
Average target price
1.140AUD
Spread / Average Target
+49.02%

Quarterly revenue - Rate of surprise